Progressive cholinergic decline in Alzheimer's Disease: consideration for treatment with donepezil 23 mg in patients with moderate to severe symptomatology
2011

Higher-Dose Donepezil for Alzheimer's Disease

Sample size: 1400 publication 10 minutes Evidence: high

Author Information

Author(s): Marwan Sabbagh, Jeffrey Cummings

Primary Institution: Banner Sun Health Research Institute

Hypothesis

Can a higher dose of donepezil improve cognitive function in patients with moderate to severe Alzheimer's disease?

Conclusion

The study found that a 23 mg dose of donepezil significantly improved cognition in patients with moderate to severe Alzheimer's disease compared to the standard 10 mg dose.

Supporting Evidence

  • The study involved over 1400 patients with moderate to severe Alzheimer's disease.
  • Patients receiving donepezil 23 mg showed significant cognitive improvement compared to those on 10 mg.
  • The higher dose was well tolerated with a safety profile typical of AChEIs.

Takeaway

This study shows that giving a higher dose of a medicine called donepezil can help people with more serious memory problems from Alzheimer's disease feel better.

Methodology

A 24-week randomized, double-blind clinical trial comparing donepezil 23 mg/d to 10 mg/d in patients with moderate to severe Alzheimer's disease.

Potential Biases

Potential bias due to the involvement of authors in advisory roles for pharmaceutical companies.

Limitations

The study primarily focused on short-term outcomes and may not reflect long-term effects of the higher dose.

Participant Demographics

Patients with moderate to severe Alzheimer's disease, with a baseline MMSE score of 0-20.

Statistical Information

P-Value

0.001

Statistical Significance

p < 0.001

Digital Object Identifier (DOI)

10.1186/1471-2377-11-21

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication